Purpose: Growth factors (GFs) and neurotrophins can decelerate retinal degeneration. This study aimed to investigate the safety, efficacy and durability of subtenon injections of autologous platelet-rich plasma (aPRP) which is a rich source of GFs in retinitis pigmentosa (RP) patients. Methods: 154 eyes of 77 RP patients with various degrees of narrowed visual field were investigated in this study. Each patient received three injections with 4-week intervals and followed for at least 12 months. The examinations and the tests were obtained before the injection, 1 month after the third injection and every 3 months during the study. The primary aim was to evaluate the effects of aPRP on visual acuity (VA) and visual functions, the second aim was to estimate the duration of the therapy effect and the need for additional aPRP injection. Results: Median age of the 77 RP patients was 35.2 ± 13.9 years. All of the eyes received 3 monthly bilateral subtenon aPRP injections. Of these patients 26 received an additional one, 12 received additional two and 1 patient received additional 3 injections with 3-month interval. There were no significant ocular or systemic side effects. The mean baseline VA was 0.22 ± 0.18 Snellen lines. It improved to 0.31 ± 0.19 following three aPRP injections, which was statistically significant. At the end of the study period, the mean VA was 0.27 ± 0.22 Snellen lines. Conclusion: The subtenon injection of aPRP might be an effective therapy and might have a positive influence in the preservation of visual functions and visual acuity of RP patients.
References
[1]
Hartong, D.T., Berson, E.L. and Dryja, T.P. (2006) Retinitis Pigmentosa. The Lancet, 368, 1795-1809. https://doi.org/10.1016/S0140-6736(06)69740-7
[2]
Oner, A. (2018) Stem Cell Treatment in Retinal Diseases: Recent Developments. Turkish Journal of Ophthalmology, 48, 33-38. https://doi.org/10.4274/tjo.89972
[3]
Kolomeyer, A.M. and Zarbin, M.A. (2014) Trophic Factors in the Pathogenesis and Therapy for Retinal Degenerative Diseases. Survey of Ophthalmology, 59, 134-165. https://doi.org/10.1016/j.survophthal.2013.09.004
[4]
Tsubota, K., Goto, E., Shimmura, S. and Shimazaki, J. (1999) Treatment of Persistent Corneal Epithelial Defect by Autologous Serum Application. Ophthalmology, 106, 1984-1989. https://doi.org/10.1016/S0161-6420(99)90412-8
[5]
Matsumoto, Y., Dogru, M., Goto, E., et al. (2004) Autologous Serum Application in the Treatment of Neurotrophic Keratopathy. Ophthalmology, 111, 1115-1120. https://doi.org/10.1016/j.ophtha.2003.10.019
[6]
Goto, E., Shimmura, S., Shimazaki, J. and Tsubota, K. (2001) Treatment of Superior Limbic Keratoconjunctivitis by Application of Autologous Serum. Cornea, 20, 807-810. https://doi.org/10.1097/00003226-200111000-00006
[7]
Noda-Tsuruya, T., Asano-Kato, N., Toda, I. and Tsubota, K. (2006) Autologous Serum Eye Drops for Dry Eye after LASIK. Journal of Refractive Surgery, 22, 61-66. https://doi.org/10.3928/1081-597X-20060101-13
[8]
Na, K.S. and Kim, M.S. (2012) Allogeneic Serum Eye Drops for the Treatment of Dry Eye Patients with Chronic Graft-versus-Host Disease. Journal of Ocular Pharmacology and Therapeutics, 28, 479-483. https://doi.org/10.1089/jop.2012.0002
[9]
De Pascale, M.R., Sommese, L., Casamassimi, A. and Napoli, C. (2015) Platelet Derivatives in Regenerative Medicine: An Update. Transfusion Medicine Reviews, 29, 52-61. https://doi.org/10.1016/j.tmrv.2014.11.001
[10]
Arslan, U., Özmert, E., Demirel, S., Örnek, F. and Şermet, F. (2018) Effects of Subtenon-Injected Autologous Platelet-Rich Plasma on Visual Functions in Eyes with Retinitis Pigmentosa: Preliminary Clinical Results. Graefe’s Archive for Clinical and Experimental Ophthalmology, 256, 893-908. https://doi.org/10.1007/s00417-018-3953-5
[11]
Ozmert, E. and Arslan, U. (2019) Management of Deep Retinal Capillary Ischemia by Electromagnetic Stimulation and Platelet-Rich Plasma: Preliminary Clinical Results. Advances in Therapy, 36, 2273-2286. https://doi.org/10.1007/s12325-019-01040-2
[12]
Marmor, M.F., Fulton, A.B., Holder, G.E., Miyake, Y., Brigell, M. and Bach, M. (2009) ISCEV Standard for Full-Field Clinical Electroretinography (2008 Update) (for the International Society for Clinical Electrophysiology of Vision). Documenta Ophthalmologica, 118, 69-77. https://doi.org/10.1007/s10633-008-9155-4
[13]
Mazzucco, L., Balbo, V., Cattana, E. and Borzini, P. (2008) Platelet Rich Plasma and Platelet Gel Preparation Using Platelet. Vox Sanguinis, 94, 202-208. https://doi.org/10.1111/j.1423-0410.2007.01027.x
[14]
Jo, C.H., Roh, Y.H., Kim, J.E., Shin, S. and Yoon, K.S. (2013) Optimizing Platelet-Rich Plasma Gel Formation by Varying Time and Gravitational Forces during Centrifugation. Journal of Oral Implantology, 39, 525-532. https://doi.org/10.1563/AAID-JOI-D-10-00155
[15]
Koenekoop, R.K. (2011) Why Some Photoreceptors Die, While Others Remain Dormant: Lessons from RPE65 and LRAT Associated Retinal Dystrophies. Ophthalmic Genetics, 32, 126-128. https://doi.org/10.3109/13816810.2010.544361
[16]
Collins, M.K., Perkins, G.R., Rodriguez-Tarduchy, G., Nieto, M.A. and López-Rivas, A. (1994) Growth Factors as Survival Factors: Regulation of Apoptosis. BioEssays, 16, 133-138. https://doi.org/10.1002/bies.950160210
[17]
LaVail, M.M., Yasumura, D., Matthes, M.T., et al. (1998) Protection of Mouse Photoreceptors by Survival Factors in Retinal Degenerations. Investigative Ophthalmology & Visual Science, 39, 592-602.
[18]
Weissmiller, A.M. and Wu, C. (2012) Current Advances in Using Neurotrophic Factors to Treat Neurodegenerative Disorders. Translational Neurodegeneration, 1, 14. https://doi.org/10.1186/2047-9158-1-14
[19]
Micera, A., Lambiase, A., Aloe, L., Bonini, S., Levi-Schaffer, F. and Bonini, S. (2004) Nerve Growth Factor Involvement in the Visual System: Implications in Allergic and Neurodegenerative Diseases. Cytokine & Growth Factor Reviews, 15, 411-417. https://doi.org/10.1016/j.cytogfr.2004.09.003
[20]
Lambiase, A. and Aloe, L. (1996) Nerve Growth Factor Delays Retinal Degeneration in C3H Mice. Graefe’s Archive for Clinical and Experimental Ophthalmology, 1, 96-100. https://doi.org/10.1007/BF02343055
[21]
Lenzi, L., Coassin, M., Lambiase, A., Bonini, S., Amendola, T. and Aloe, L. (2005) Effect of Exogenous Administration of Nerve Growth Factor in the Retina of Rats with Inherited Retinitis Pigmentosa. Vision Research, 45, 1491-1500. https://doi.org/10.1016/j.visres.2004.12.020
[22]
Lambiase, A., Aloe, L., Centofanti, M., et al. (2009) Experimental and Clinical Evidence of Neuroprotection by Nerve Growth Factor Eye Drops: Implications for Glaucoma. Proceedings of the National Academy of Sciences of the United States of America, 106, 13469-13474. https://doi.org/10.1073/pnas.0906678106
[23]
Lambiase, A., Mantelli, F., Sacchetti, M., Rossi, S., Aloe, L. and Bonini, S. (2011) Clinical Applications of NGF in Ocular Diseases. Archives Italiennes de Biologie, 149, 283-292.
[24]
Sachetti, M., Mantelli, F., Rocco, M.L., et al. (2017) Recombinant Human Nerve Growth Factor Treatment Promotes Photoreceptor Survival in the Retinas of Rats with Retinitis Pigmentosa. Current Eye Research, 42, 1064-1068. https://doi.org/10.1080/02713683.2017.1279634
[25]
Benedetto, F., Giancarlo, I., Antonio, C., et al. (2016) NGF Eye-Drops Topical Administration in Patients with Retinitis Pigmentosa, a Pilot Study. Journal of Translational Medicine, 9, 14-18. https://doi.org/10.1186/s12967-015-0750-3
[26]
Wen, R., Tao, W., Li, Y. and Sieving, P.A. (2012) CNTF and Retina. Progress in Retinal and Eye Research, 31, 136-151. https://doi.org/10.1016/j.preteyeres.2011.11.005
[27]
Cayouette, M., Behn, D., Sendtner, M., Lachapelle, P. and Gravel, C. (1998) Intraocular Gene Transfer of Ciliary Neurotrophic Factor Prevents Death and Increases Responsiveness of Rod Photoreceptors in the Retinal Degeneration Slow Mouse. Journal of Neuroscience, 18, 9282-9293. https://doi.org/10.1523/JNEUROSCI.18-22-09282.1998
[28]
Tao, W., Wen, R., Goddard, M.B., et al. (2002) Encapsulated Cell-Based Delivery of CNTF Reduces Photoreceptor Degeneration in Animal Models of Retinitis Pigmentosa. Investigative Ophthalmology & Visual Science, 43, 3292-3298.
[29]
Sieving, P.A., Caruso, R.C., Tao, W., et al. (2006) Ciliary Neurotrophic Factor (CNTF) for Human Retinal Degeneration: Phase I Trial of CNTF Delivered by Encapsulated Cell Intraocular Implants. Proceedings of the National Academy of Sciences of the United States of America, 103, 3896-3901. https://doi.org/10.1073/pnas.0600236103
[30]
Talcott, K.E., Ratnam, K., Sundquist, S.M., et al. (2011) Longitudinal Study of Cone Photoreceptors during Retinal Degeneration and in Response to Ciliary Neurotrophic Factor Treatment. Investigative Ophthalmology & Visual Science, 52, 2219-2226. https://doi.org/10.1167/iovs.10-6479
[31]
Birch, D.G., Weleber, R.G., Duncan, J.L., Jaffe, G.J. and Tao, W. (2013) Ciliary Neurotrophic Factor Retinitis Pigmentosa Study Groups. Randomized Trial of Ciliary Neurotrophic Factor Delivered by Encapsulated Cell Intraocular Implants for Retinitis Pigmentosa. American Journal of Ophthalmology, 156, 283-292. https://doi.org/10.1016/j.ajo.2013.03.021
[32]
Birch, D.G., Bennett, L.D., Duncan, J.L., Weleber, R.G. and Pennesi, M.E. (2016) Long-Term Follow-Up of Patients with Retinitis Pigmentosa (RP) Receiving Intraocular Ciliary Neurotrophic Factor Implants. American Journal of Ophthalmology, 170, 10-14. https://doi.org/10.1016/j.ajo.2016.07.013
[33]
Kyhn, M.V., Klassen, H., Johansson, U.E., et al. (2009) Delayed Administration of Glial Cell Line-Derived Neurotrophic Factor (GDNF) Protects Retinal Ganglion Cells in a Pig Model of Acute Retinal Ischemia. Experimental Eye Research, 89, 1012-1020. https://doi.org/10.1016/j.exer.2009.08.014
[34]
Politi, L.E., Rotstein, N.P. and Carri, N.G. (2001) Effect of GDNF on Neuroblast Proliferation and Photoreceptor Survival: Additive Protection with Docosahexaenoic Acid. Investigative Ophthalmology & Visual Science, 42, 3008-3015.
[35]
Ohnaka, M., Miki, K., Gong, Y.Y., et al. (2012) Long-Term Expression of Glial Cell Line-Derived Neurotrophic Factor Slows, But Does Not Stop Retinal Degeneration in a Model of Retinitis Pigmentosa. Journal of Neurochemistry, 122, 1047-1053. https://doi.org/10.1111/j.1471-4159.2012.07842.x
[36]
Alio, J.L., Arnalich-Montiel, F. and Rodriguez, A.E. (2012) The Role of “Eye Platelet Rich Plasma” (E-PRP) for Wound Healing in Ophthalmology. Current Pharmaceutical Biotechnology, 13, 1257-1265. https://doi.org/10.2174/138920112800624355
[37]
Anitua, E., Andia, I., Ardanza, B., Nurden, P. and Nurden, A.T. (2004) Autologous Platelets as a Source of Proteins for Healing and Tissue Regeneration. Thrombosis and Haemostasis, 91, 4-15. https://doi.org/10.1160/TH03-07-0440
